Plasma brain natriuretic peptide - An independent predictor of cardiovascular mortality in acute heart failure

European Journal of Heart Failure

Volumn 1, Issue 1, 2000, Pages 59-65

  Yu, Cheuk M ^a   Sanderson, John E ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atrial natriuretic factor; Brain natriuretic factor; Heart failure; Prognosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART FAILURE; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEATH; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG ARTERY PRESSURE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RISK ASSESSMENT; SEX; STATISTICAL ANALYSIS;

ATRIAL NATRIURETIC FACTOR; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0033086889     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(98)00010-5     Document Type: Article

References (34)

1. Pattersson A, Hedner J, Held P, Swedberg K, Towle AC. Increased plasma levels of atrial natriuretic peptide in patients with congestive heart failure. Eur Heart J 1986;7:693-696.
2. Fyhrquist F, Tikkanen I. Atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1988;62:20A-24A.
3. Sugawara A, Nakao K, Morii N et al. Synthesis of atrial natriuretic polypeptide in human failing hearts-evidence of altered processing of atrial natriuretic polypeptide precursor and augmented synthesis of beta-human ANP. J Clin Invest 1988;6:1962-1970.
4. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
5. Arad M, Elazar E, Shotan A, Klein R, Rabinowitz B. Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure. Cardiology 1996;87:12-17.
6. Nakao K, Mukoyama M, Hosoda K et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;59:1500-1506.
7. Wei CM, Heublein DM, Perrella MA et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-1009.
8. Stevens TL, Rasmussen TE, Wei CM, Kinoshita M, Matsuda Y, Burnett JC, Jr. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Cardiac Failure 1996;2:119-125.
9. Svanegaard J, Angelo-Nielsen K, Pindborg T. Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction. Br Heart J 1992;68:38-42.
10. Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-1969.
11. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696-710.
12. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997;77:264-267.
13. Haass M, Dietz R, Fischer TA, Lang RE, Kubler W. Role of right and left atrial dimensions for release of atrial natriuretic peptide in left-sided valvular heart disease and idiopathic dilated cardiomyopathy. Am J Cardiol 1988;62:764-770.
14. Lee RW, Gay RG, Moffett C, Johnson DG, Goldman S. Atrial natriuretic peptide levels during development of chronic heart failure after myocardial infarction in rats. Life Sci 1987;40:2025-2030.
15. Tsutamoto T, Bito K, Kinoshita M. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J 1989;117:599-606.
16. Hara H, Ogihara T, Nakamaru M, Rakugi H, Tateyama H. Changes in the levels of plasma atrial natriuretic peptide, hemodynamic measurements, and the levels of vasoactive hormones during the clinical course congestive of heart failure. Clin Cardiol 1988;11:743-747.
17. Cleland JGF, Cowburn PJ, Morgan K. Neuroendocrine activation after myocardial infarction: Causes and consequences. Heart 1996;3:53-59.
18. Hall C, Rouleau JL, Moye L et al. N-terminal proatrial natriuretic factor - An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934-1942.
19. Rouleau JR, Packer M, Moye L et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994;24:583-591.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-1736.
21. Omland T, Bonarjee VVS, Nilsen DWT et al. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: Comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993;70:409-414.
22. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-1539.
23. Yu CM, Sanderson JE, Shum IO et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996;17:1694-1702.
24. Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994;24:132-139.
25. Yu CM, Sanderson JE. Different prognostic significance of right and left ventricular diastolic dysfunction in heart failure. Clin Cardiol, in press.
26. Krupienicz A. Elevated plasma levels of atrial natriuretic peptide (ANP) as a possible aggravating agent in congestive heart failure. Med Hypotheses 1989;28:11-12.
27. Kentsch M, Drummer C, Gerzer R, Muller-Esch G. Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure. Eur J Clin Invest 1995;25:281-283.
28. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994;89:2232-2240.
29. Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail 1996;2:S277-S285.
30. Poulos JE, Gower WR, Jr, Sullebarger JT, Fontanet HL, Vesely DL. Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res 1996;32:909-919.
31. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-469.
32. Mantymaa P, Voulteenaho O, Martilla M, Ruskoaho H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 1993;133:1470-1473.
33. Okolicany J, McEnroe GA, Koh GY, Lewicki JA, Maack T. Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol 1992;263:F546-F553.
34. Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: Indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992;82:619-623.